Efficacy And Safety Of Infliximab Combined With Azathioprine In The Treatment Of Crohn’s Disease:a Meta-Analysis

OBJECTIVE:To evaluate the efficacy and safety of infliximab combined with azathioprine in the treatment of Crohn’s disease(CD) by meta-analysis.METHODS:Randomized controlled trials of IFX combined with AZA in the treatment of patients with CD were retrieved from Pubmed,EMBASE, Cochrane, CBM and VIP database. Methodological quality of trials was assessed according to Jadad scale. Analyze the clinical remission rate, mucosal healing rate and the incidence of adverse reactions by Revman 5.2 software.RESULTS:Four studies(RCTs) with a sample size of 752 patients were enrolled into the analysis.The meta-analysis showed that the rate of clinical remission and mucosal healing of IXF+AZA group were higher than IXF or AZA monotherapy[OR=2.38,95%CI (1.75,3.25), P< 0.00001; OR=2.35,95%CI (1.52,3.62), P=0.0001]. There was no difference in side effect of medicine between IFX+AZA group and IFX or AZA monotherapy group[OR=1.18,95%CI (0.46,2.99); P=0.73].CONCLUSION:Infliximab combined with azathioprine was more effective than Infliximab or azathioprine monotherapy in the treatment of Crohn’s disease.There was no difference in side effect of medicine between combination group and IFX or AZA monotherapy group.